Regeneron Pharmaceuticals, Inc. (REGN)

Sector: Healthcare
Industry: Pharmaceutical Preparations
Country: United States
Exchange: NASDAQ
Market cap: $95.50B
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
Latest financial period: September 30, 2026
Filed with the SEC: October 30, 2026
Estimated earnings date: Not available
Profit #455 of 1421 companies
| | Sep 26 | Jun 26 | Mar 26 | Dec 25 |
|---|
| ROE/ROA | 68.6% | 68.2% | 70.4% | 71.3% |
Growth #608 of 1421 companies
Payout #141 of 1421 companies
Safety #12 of 1421 companies
Price #638 of 1421 companies